INDUSTRY × Interventional × Head & Neck × Clear all
NCT07623369 2026-06-03

A First-in-Human Study of HH160 in Patients With Advanced Solid Tumors

Huahui Health

Phase 1 Not yet recruiting
56 enrolled
NCT07623642 2026-06-03

A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.

GV20 Therapeutics

Phase 2 Not yet recruiting
227 enrolled
NCT02568267 2026-05-27

STARTRK-2

Hoffmann-La Roche

Phase 2 Active not recruiting
534 enrolled 1 FDA
NCT03093116 2026-05-27

TRIDENT-1

Turning Point Therapeutics, Inc.

Phase 1/2 Recruiting
500 enrolled 2 FDA